Limitations in Clinical Translation of Nanoparticle-Based Gene Therapy

Organic nanoparticle-based (ONP) gene therapy is a potential strategy to cure human cancer. However, there are still many practical barriers before the promising results from in vitro and preclinical studies can be translated to clinical success. We discuss the reasons behind the hesitant uptake by...

Full description

Saved in:
Bibliographic Details
Published in:Trends in biotechnology (Regular ed.) 2017-12, Vol.35 (12), p.1124-1125
Main Authors: Wong, Joanna K.L., Mohseni, Rashin, Hamidieh, Amir Ali, MacLaren, Robert E., Habib, Nagy, Seifalian, Alexander M.
Format: Article
Language:English
Subjects:
Cancer
Cancer therapies
Cell adhesion & migration
Clinical trials
Clinical Trials as Topic
Drug dosages
Drug-Related Side Effects and Adverse Reactions
Gene therapy
Gene Transfer Techniques
Genetic Heterogeneity
Genetic Therapy - methods
Humans
limitations
Nanomaterials
Nanoparticles
Neoplasms - therapy
organic nanoparticle
Patients
Sensitivity and Specificity
Studies
Translational Medical Research
Treatment Outcome
Trends
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Organic nanoparticle-based (ONP) gene therapy is a potential strategy to cure human cancer. However, there are still many practical barriers before the promising results from in vitro and preclinical studies can be translated to clinical success. We discuss the reasons behind the hesitant uptake by the clinic.
ISSN:0167-7799
1879-3096
DOI:10.1016/j.tibtech.2017.07.009